News | April 04, 2025
SPARC announces submission of IND Application for SBO-154 to USFDA
The IND application supports the next phase of development of SBO-154
The IND application supports the next phase of development of SBO-154
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
PRX-PLUS has a unique product feature with its deep-impacting formula
The consignment of USFDA qualified Metformin (1000mg) was received by the province of Mendoza for distribution in the public health system
GE HealthCare’s Revolution Vibe CT enables more facilities to elevate patient care by offering advanced cardiac imaging technology
The new combination therapy offers a dual mechanism of action for superior intraocular pressure control
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Positions Curium as leading manufacturer of Lu-177 isotope
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
Subscribe To Our Newsletter & Stay Updated
